Asahi Kasei aims for global market through Phase III trials with novel anticoagulant
This article was originally published in Scrip
Executive Summary
The diversified Japanese materials group Asahi Kasei is planning to take its recombinant human thrombomodulin-alfa product ART-123 into the global arena through the start of an international Phase III trial for the treatment of severe sepsis and coagulopathy.